The Swiss company's asthma triplet is now approved in Europe and Japan but Enerzair is well behind GSK's rival LABA/LAMA/ICS in the US where Novartis's product has not even been submitted yet.

Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.

Company did not kill its development program because of US FDA feedback, but the experience seems to be another lesson in the difficulty in gaining approval for complex generics.

Sandoz has decided to discontinue development of its generic version of GlaxoSmithKline’s Advair Diskus respiratory brand, resulting in an impairment charge of $442m.